NeuroQuant® is a fully automated advanced imaging software that provides segmentation and quantification from brain MRI, revealing various biomarkers. Values are compared to a unique normative database of patients of the same age and sex and similar intracranial volume to aid in making clinical decisions regarding neurodegenerative diseases.
Product specifications Information source: Vendor
Last updated: Jan. 21, 2021
Product name NeuroQuant
Subspeciality Neuro
Modality MR
Disease targeted Neurodegenerative brain disorders
Key-features Brain region quantification (75 structures), brain change data, normative data comparisons, dynamic atlas, custom report options
Suggested use Before: flagging acute findings
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand)
Data characteristics
Population Patients aged 3-100 with suspicion of atrophy, edema, or abnormal brain development
Input 3D T1 sagittal MR sequence
Input format DICOM
Output segmentation overlays, brain change overlay, quantitative report with structure volumes, structure change data, and normative comparisons
Output format DICOM
Integration Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time > 10 minutes
Certified, Class IIa , MDD
510(k) cleared, Class II
Market presence
On market since 08-2006
Distribution channels Blackford, Nuance, Eureka Clinical AI, Olea Medical, GE Healthcare, GMP, Getz Healthcare, Philips Intellispace
Countries present (clinical, non-research use) 43
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use, Subscription
Based on Number of installations, Number of analyses
Peer reviewed papers on performance

  • Deep Learning Enables 60% Accelerated Volumetric Brain MRI While Preserving Quantitative Performance: A Prospective, Multicenter, Multireader Trial (read)

  • High-throughput, Fully Automated Volumetry for Predictionof MMSE and CDR Decline in Mild Cognitive Impairment (read)

  • Fully-automated volumetric MRI withnormative ranges: Translation to clinicalpractice (read)

  • Fully-Automated Quantification of Regional BrainVolumes for Improved Detection of Focal Atrophyin Alzheimer Disease (read)

  • Comparison of Automated Brain Volume Measures obtained withNeuroQuantR_x0002_and FreeSurfer (read)

Non-peer reviewed papers on performance

  • White paper: The Importance of Quantitative Volumetric Analysis for Brain MRI - 10 Years of Clinical Practice (read)

  • White paper: The NeuroQuantNormative Database - Comparing Individual Brain Structures (read)

  • White paper: Dynamic Atlas™ - The New Personalized Segmentation Approach (read)

Other relevant papers